A Place for Hope

Adil Daud, M.D.

Melanoma specialist

 Dr. Adil Daud, an oncologist, is co-director of the Melanoma Center and a specialist in melanoma and other skin cancers. In addition to caring for patients, he directs melanoma research to better understand the biology of melanoma and to develop new treatments for the disease. Daud has developed and led many clinical trials that have expanded the use of gene therapy for melanoma.

Daud earned a medical degree at the Government Medical College in Nagpur, India. He completed an internship and residency in internal medicine at Indiana University Medical Center, followed by a fellowship in hematology-oncology at Memorial Sloan-Kettering Cancer Center. Prior to joining UCSF Medical Center, he was a researcher at the Moffitt Cancer Center in Tampa, Fla. for seven years. Daud has won numerous awards, including the American Society for Clinical Oncology's Young Investigator award and Castle Connolly's Best Doctors in America award. He is a professor of hematology-oncology at UCSF.

 

Alain Algazi, M.D.

Melanoma specialist

 

Dr. Algazi is an Assistant Professor in the Cutaneous Oncology Program at The University of California San Francisco and the Principal Investigator for a several clinical trials for patients with advanced and metastatic melanoma. These trials include “A phase 2 trial of dabrafenib and trametinib with stereotactic radiosurgery in BRAF mutant melanoma brain metastases” and “BKM120 combined with vemurafenib in BRAF mutant advanced melanoma” for patients with disease progression on vemurafenib alone. He also contributed to several pivotal clinical trials recently including two published in the New England Journal of Medicine in 2012 regarding BRAF inhibitor combination therapy and PD-1 antibody therapy for patients with advanced melanoma. He was awarded a fellowship grant from the American Cancer Society for his work in melanoma research, and he is an active contributing member of the Southwest Oncology Group (SWOG) melanoma committee.

Dr. Algazi received his medical degree from the University of California, Los Angeles, where he also completed his internship and residency in internal medicine. He completed a fellowship in hematology and oncology at the University of California, San Francisco where he was subsequently recruited as a member of the full time faculty.

His research interests include clinical trials of targeted therapies for melanoma based in the latest laboratory data emerging from UCSF and elsewhere. His most recent initiative is SWOG trial S1320: a randomized phase 2 trial of intermittent versus continuous dosing of dabrafenib and trametinib for patients with BRAF mutant melanoma. This study will open at participating sites nationwide by the end of the 2013. He is also working to develop new strategies for treating melanoma brain metastases.

 

 

Katy Tsai, M.D.

Clinical Fellow

 

Mike Buljan, NP

Nurse Practitioner

 Michael Buljan is the practice nurse for the Melanoma Oncology Group at UCSF and Co-Investigator on our clinical trials. Michael earned his bachelors degree in communications from California State University, Sacramento. He went on to earn a masters’ degree in nursing from San Franicisco State University and he completed the adult nurse practitioners program at University or California, San Francisco. Prior to working at UCSF, Michael worked at San Francisco General Hospital as a nurse practitioner at the oncology infusion center and as an HIV nurse.

 

 

 

Jade Yen, CCRP

Program Manager

 Jade Yen began her career in clinical research at the Massachusetts General Hospital Cancer Center in 2010. She specialized in personalized medicine, targeted therapies, and maintained the integrity of Thoracic, GI, and Head and Neck studies. Her areas of expertise include: complete trial management, improving operational efficiencies to meet regulatory standards specific to sponsor audits, and has first-hand experience in the accelerated FDA approval of Xalkori and Keytruda. Jade is now the Program Manager in the Melanoma and Cutaneous Oncology Department at UCSF. She is a Certified Clinical Research Professional (CCRP), holds a B.S. in Hospitality Management from Cal Poly Pomona and completed her Post Baccalaureate at Harvard University in Biomedical Sciences.

 

 

Adele Hobbs Muthukumar, CCRP

Lead Clinical Research Coordinator

 

Adele is the Lead CRC in the Cutaneous Oncology Group at the UCSF Helen Diller Family Comprehensive Cancer Center.  In this capacity, she oversees day to day operations of Melanoma Clinical Research including study initiation, patient accrual, protocol maintenance, and data entry and management, particularly with multi-institutional clinical trials. Adele earned her master’s degree in Epidemiology from Temple University in 2010 and her bachelor’s degree in Life Science from The Pennsylvania State University in 2006. Prior to joining UCSF, Adele directed a research team studying the effects and outcomes of minimally-invasive robotic surgery among prostate cancer patients at The Mount Sinai Medical Center and Lenox Hill Hospital, both in New York, NY.

 

 

Neharika Khurana

Clinical Research Coordinator

 Neharika Khurana just recently joined the Cutaneous Oncology Group at the UCSF Helen Diller Family Comprehensive Cancer Center as a clinical research coordinator. Neharika has 1.5 years experience managing industry sponsored clinical trials within the field of infectious diseases. By joining the cancer center, she hopes to expand her knowledge about the oncology field.

She received her B.S. in Neurobiology, Physiology, and Behavior from UC Davis and then received her M.S. in Biomedical Sciences from Rosalind Franklin University of Medicine and Science.

 

CC # 11854 “A Multicenter Phase II Trial of intratumoral pIL-12 electroporation in advanced stage cutaneous and in transit malignant melanoma”

CC# 10861: A Multicenter Phase II Trial of Intratumoral IL12 Plasmid Electroporation In Cutaneous Lymphoma

 

Kimberly Loo

Clinical Research Coordinator

Currently managing:

CC# 14851: A Phase I Open-Label Study of Safety and Tolerability of MEDI4736 in Subjects with Metastatic or Unresectable Melanoma in Combination with Dabrafenib and Trametinib or with Trametinib Alone

CC#10857: An Open-Label, Dose-Escalation, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the BRAF Inhibitor GSK2118436 in Combination with the MEK Inhibitor GSK1120212 in Subjects with BRAF Mutant Metastatic Melanoma

CC#12857: A Phase 2 prospective trial of dabrafenib and trametinib with stereotactic radiosurgery in BRAF mutant melanoma brain metastases

CC# 138510; Tissue Bank of Human Biospecimens for Molecular Studies of Mechanisms of Resistance or Response to Therapy in Melanoma and Other Solid Tumors: UCSF Melanoma Tissue Bank (MTB) 

 

Yasaman Zia

Clinical Research Coordinator

CC#11857: Phase I Study of Single Agent MK-3475 in Patients with Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, and Non-Small Cell Lung Carcinoma

CC#12859: Randomized Phase II Study of MK-3475 versus Chemotherapy in Patients with Advanced Melanoma

Siu Chaw

Clinical Research Coordinator

CC#13853: A Multicenter, Randomized, Controlled, Two-Arm, Phase III Study to Evaluate the Safety and Efficacy of MK-3475 Compared to Ipilimumab in Patients with Advanced Melanoma

June Kristine Winters

Clinical Research Coordinator

CTSU S1320: A Randomized Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib and Trametinib in BRAF V600E/K Melanoma

CC#14854 / Merck 030: Expanded Access of MK-3475 in Metastatic Melanoma Patients with Limited to No Treatment Options

 

Shamim Hasham

Clinical Research Coordinator

CC# 128510 (CA209037): A Randomized, Open-Label Phase 3 Trial of BMS-936558 (Nivolumab) versus Investigator's Choice in Advanced (Unresectable or Metastatic) Melanoma Patients Progressing Post Anti-CTLA-4 Therapy

 

CC# 13854 (CA209067): A Phase 3, Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined with Ipilimumab Versus Ipilimumab Monotherapy in Subjects with Previously Untreated Unresectable or Metastatic Melanoma.

 

CC# 129813: Microbiome Analysis of the Gut in Cancer Patients Treated with Ipilimumab

 

CC#11858: Mechanism of pyrexia syndrome and immune response in patients treated with GSK 2118436 +GSK1120212 (BRF113220) or with BRAF, MEK, ERK, or immune checkpoint inhibition

 

 

Lawrence Chen, MA 

Practice Assistant

 

Lawrence Chen is the practice assistant for the Melanoma Oncology Group at UCSF. Lawrence earned his bachelors and masters degrees in molecular biology from the University of Pacific in Stockton.  Before coming to UCSF, Lawrence worked at the Paul Hom Asian Clinic in Sacramento, California serving medically indigent patients with language barriers.

 

.